Medivation, Inc. (MDVN) Names Stephen Kelsey Senior Vice President of New Projects

SAN FRANCISCO, CA--(Marketwired - May 13, 2013) - Medivation, Inc. (NASDAQ: MDVN) today announced that Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path. will join Medivation in the newly-created position of senior vice president of new projects, reporting to Dr. David Hung, M.D., Medivation's president and chief executive officer.

"Stephen Kelsey is an extremely well-respected and prolific product development executive with an impressive track record of successfully developing Perjeta, Kadcyla and Erivedge and playing a significant role in the development of blockbuster products such as Rituxan (chronic lymphocytic leukemia) and Herceptin (TCH regimen)," said David Hung, M.D., president and chief executive officer of Medivation, Inc. "We are delighted to have him as part of our team and to leverage his expertise as we accelerate our current efforts to expand our clinical portfolio and drive new products into the clinic."

"Medivation's productive internal research efforts to date have generated a number of intriguing compounds in areas that address large markets with significant unmet needs," said Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path. "I am excited to join the team to help Medivation advance a clinical portfolio of innovative and diverse product candidates."

Stephen M. Kelsey joins Medivation from Geron Corporation where he served as the executive vice president, research & development and chief medical officer. From 2009 to 2011 he served as executive vice president and chief medical officer, oncology at Geron. From 2002 to 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as vice president, clinical hematology/oncology, where he was responsible for the oncology late stage development portfolio including Rituxan®, Herceptin®, Tarceva®, Perjeta®, Kadcyla™, Erivedge® and five additional development products in solid tumors and hematologic malignancies. From 2000 to 2002, Dr. Kelsey was the director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.), where he was responsible for Sutent®, and director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the University of Birmingham in the United Kingdom.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at

Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900